![Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Analysis of extracts from HepG2 cells treated with PMA and MCF cells.](http://images.novusbio.com/fullsize/ErbB2-Her2-[p-Tyr1248]-Antibody-Western-Blot-NB100-81960-img0012.jpg "Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Analysis of extracts from HepG2 cells treated with PMA and MCF cells.")
| Reactivity | Hu, Mu, RtSpecies Glossary |
| Applications | WB, ICC/IF, IHC |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 1.0 mg/ml |
| Immunogen | The antiserum was produced against synthesized phosphopeptide derived from human ErbB2/Her2 around the phosphorylation site of tyrosine1248 (P-E-YP-L-G). |
| Modification | p Tyr1248 |
| Specificity | Detects endogenous levels of ErbB2/Her2 only when phosphorylated at tyrosine1248. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | ERBB2 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Theoretical MW | 180 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||
| Control |
|
||
| Publications |
|
| Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
| Buffer | PBS, 50% glycerol, 0.5% BSA |
| Preservative | 0.02% Sodium Azide |
| Concentration | 1.0 mg/ml |
| Purity | Immunogen affinity purified |
![Immunohistochemistry EGFR Antibody [Unconjugated]](https://images.novusbio.com/images2/EGF_R_AF231_Immunohistochemistry_20892.jpg)
![Immunocytochemistry EGFR Antibody [Unconjugated]](https://images.novusbio.com/images2/EGF_R_AF231_Immunocytochemistry__Immunofluorescence_21143.jpg)
![Western Blot EGFR Antibody [Unconjugated]](https://images.novusbio.com/images2/EGF_R_AF231_Western_Blot_19925.jpg)
![Western Blot AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/Akt3_AF887_Western_Blot_5930.jpg)
![Simple Western AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/16332.jpg)
![Intracellular Staining by Flow Cytometry AKT [p Ser473] Antibody [Unconjugated] - Pan Specific](https://images.novusbio.com/images2/Akt3_AF887_Flow_Cytometry_8283.jpg)
![Neutralization ErbB3/Her3 Antibody (66223) [Unconjugated]](https://images.novusbio.com/images2/ErbB3_MAB3481_Block_Neutralize_9158.jpg)
Secondary Antibodies |
Isotype Controls |
Research Areas for ErbB2/Her2 Antibody (NB100-81960)Find related products by research area.
|
|
Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach... Read full blog post. |
|
NPC1: A Potential Target For Triple-Negative Breast Cancer By Natalia Gurule, PhD Breast Cancer is a Heterogeneous DiseaseBreast cancer is the most frequently identified malignancy in women, accounting for 30% of diagnosed cases of cancer in women in the US annuall... Read full blog post. |
|
Hypoxia-Dependent CAR Stabilizing Construct in T cells Improves Solid Tumor Targeting and Efficacy By Victoria Osinski, PhDDespite advances in the development of cancer immunotherapies, those specifically targeting tumors still remains limited. Currently, there is great interest in utilizing chimeric antigen rece... Read full blog post. |
|
Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy By Victoria Osinski, PhDWhat’s “Natural” About Natural Killer (NK) Cells?For immunologists, the term cytotoxicity often conjures up images of an army of antigen specific CD8+ T cells deploying to ... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Human breast carcinoma tissue.](http://images.novusbio.com/fullsize/ErbB2-Her2-[p-Tyr1248]-Antibody-Immunohistochemistry-Paraffin-NB100-81960-img0011.jpg "Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Human breast carcinoma tissue.")
![Immunocytochemistry/Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Staining of methanol-fixed MCF7 cells using HER2 phospho-antibody.](http://images.novusbio.com/fullsize/ErbB2-Her2-[p-Tyr1248]-Antibody-Immunocytochemistry-Immunofluorescence-NB100-81960-img0007.jpg "Immunocytochemistry/Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Staining of methanol-fixed MCF7 cells using HER2 phospho-antibody.")
![Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Human lung carcinoma tissue.](http://images.novusbio.com/fullsize/ErbB2-Her2-[p-Tyr1248]-Antibody-Immunohistochemistry-Paraffin-NB100-81960-img0010.jpg "Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Human lung carcinoma tissue.")
![Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using NB100-81960. The picture on the right is blocked with the phospho peptide.](http://images.novusbio.com/fullsize/nb100-81960_rabbit-polyclonal-erbb2-her2-p-tyr1248-antibody-23420241446224.jpg "Immunohistochemistry-Paraffin: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using NB100-81960. The picture on the right is blocked with the phospho peptide.")
![Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western blot analysis of lysates from HepG2 cells treated with PMA 125ng/ml 30', using NB100-81960. The lane on the right is blocked with the phospho peptide.](http://images.novusbio.com/fullsize/nb100-81960_rabbit-polyclonal-erbb2-her2-p-tyr1248-antibody-23420241520580.jpg "Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western blot analysis of lysates from HepG2 cells treated with PMA 125ng/ml 30', using NB100-81960. The lane on the right is blocked with the phospho peptide.")
![Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western Blot analysis of 293 cells using NB100-81960 diluted at 1: 1000](http://images.novusbio.com/fullsize/nb100-81960_rabbit-polyclonal-erbb2-her2-p-tyr1248-antibody-23420241545355.jpg "Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western Blot analysis of 293 cells using NB100-81960 diluted at 1: 1000")
![Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western blot analysis of lysates from HepG2 cells treated with PMA 125ng/ml 30', using NB100-81960. The lane on the right is blocked with the phospho peptide.](http://images.novusbio.com/fullsize/nb100-81960_rabbit-polyclonal-erbb2-her2-p-tyr1248-antibody-23420241545357.jpg "Western Blot: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Western blot analysis of lysates from HepG2 cells treated with PMA 125ng/ml 30', using NB100-81960. The lane on the right is blocked with the phospho peptide.")
![Immunocytochemistry/ Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Mutant ERBB2 cooperates with loss of p53 & leads to papillary GBC in recipient mice. (A) Top: Schematic of human ERBB2, indicating the location of two point mutants (S310F & V777L). Bottom: retroviral vector used to transduce organoids, that had been treated with an sgp53-containing plasmid (px459) to induce loss of p53. (B) Immunofluorescence for ERBB2 (top) & phospho-ERBB2 (bottom) on organoids harboring the indicated genetic alterations. (C) Tumor volumes 36 days after s.c. implantation of the respective organoids into recipient mice. All mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids exhibited tumor development, whereas sgp53;empty vector- & sgp53;ERBB2wildtype organoids did not give rise to tumors over a four-month observation period. There was no significant difference in the tumor burden of mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids (p = 0.999). (D) Mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids reached endpoint criteria with a median survival of 79.5 days & 58.5 days, respectively. (E) H&E & IHC for CK19 & EGFP on tumors generated with sgp53;ERBB2S310- & sgp53;ERBB2V777L organoids. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31795490), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-81960_rabbit-polyclonal-erbb2-her2-p-tyr1248-antibody-310202416284926.jpg "Immunocytochemistry/ Immunofluorescence: ErbB2/Her2 [p Tyr1248] Antibody [NB100-81960] - Mutant ERBB2 cooperates with loss of p53 & leads to papillary GBC in recipient mice. (A) Top: Schematic of human ERBB2, indicating the location of two point mutants (S310F & V777L). Bottom: retroviral vector used to transduce organoids, that had been treated with an sgp53-containing plasmid (px459) to induce loss of p53. (B) Immunofluorescence for ERBB2 (top) & phospho-ERBB2 (bottom) on organoids harboring the indicated genetic alterations. (C) Tumor volumes 36 days after s.c. implantation of the respective organoids into recipient mice. All mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids exhibited tumor development, whereas sgp53;empty vector- & sgp53;ERBB2wildtype organoids did not give rise to tumors over a four-month observation period. There was no significant difference in the tumor burden of mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids (p = 0.999). (D) Mice transplanted with sgp53;ERBB2S310F- & sgp53;ERBB2V777L organoids reached endpoint criteria with a median survival of 79.5 days & 58.5 days, respectively. (E) H&E & IHC for CK19 & EGFP on tumors generated with sgp53;ERBB2S310- & sgp53;ERBB2V777L organoids. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31795490), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry Progesterone R/NR3C3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Progesterone_R_AF5415_Immunocytochemistry__Immunofluorescence_20674.jpg)
![Immunohistochemistry Progesterone R/NR3C3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Progesterone_R_AF5415_Immunohistochemistry_20779.jpg)
![Western Blot Progesterone R/NR3C3 Antibody [Unconjugated]](https://images.novusbio.com/images2/Progesterone_R_AF5415_Western_Blot_5715.jpg)
![SDS-PAGE EGF [Unconjugated]](https://images.novusbio.com/images2/EGF_236-EG_234.jpg)
![Bioactivity EGF [Unconjugated]](https://images.novusbio.com/images2/EGF_236EG_1570.jpg)
![Cell Culture EGF [Unconjugated]](https://images.novusbio.com/images/236-eg_recombinant-human-egf-protein-cf-bioactivity-25202394053.jpg)
![Immunocytochemistry ErbB4/Her4 Antibody (182803) [Unconjugated]](https://images.novusbio.com/images2/ErbB4_MAB1131_Immunocytochemistry__Immunofluorescence_21145.jpg)
![Immunohistochemistry ErbB4/Her4 Antibody (182803) [Unconjugated]](https://images.novusbio.com/images2/ErbB4_MAB1131_Immunohistochemistry_12968.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/DATA_VEGF_DVE00_ELISA_871.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/DATA_VEGF_DVE00_ELISA_872.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/VEGF_DVE00_ELISA_208.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")